Jatenzo Cost in Massachusetts 2026: Cash Price, Insurance, and Savings Options

What Is Jatenzo and Why Does the Price Matter in Massachusetts?

Jatenzo is the first FDA-approved oral testosterone therapy in the United States designed to avoid first-pass hepatic metabolism by using a lymphatic absorption pathway. Tolmar Pharmaceuticals received FDA approval in March 2019 for Jatenzo (testosterone undecanoate) capsules to treat adult males with conditions associated with a deficiency or absence of endogenous testosterone, including primary hypogonadism and hypogonadotropic hypogonadism. The FDA prescribing information is available at accessdata.fda.gov.

Massachusetts ranks among the most expensive states for specialty pharmacy costs overall, making price transparency especially relevant for residents evaluating testosterone replacement options. The state also has a complex Medicaid field under MassHealth, which covers more than 2 million residents.

How Jatenzo Differs From Injections and Gels

Unlike intramuscular testosterone cypionate or enanthate, Jatenzo is swallowed twice daily with a meal or snack containing at least 10 to 19 grams of fat. Absorption occurs through intestinal lymphatics, bypassing the liver and avoiding the hepatotoxicity associated with older oral 17-alpha-alkylated androgens such as methyltestosterone. The pharmacokinetics were characterized in the key PLUS trial (N=166), reported by Swerdloff et al. In the Journal of Clinical Endocrinology and Metabolism. That study found 87% of subjects achieved average testosterone concentrations within the normal range (300 to 1,000 ng/dL) at steady state 1.

Dosing and Titration in Brief

The starting dose is 237 mg twice daily. After 28 days, a morning serum testosterone is drawn. If the level exceeds 1,050 ng/dL, the dose drops to 158 mg twice daily. If the level falls below 300 ng/dL, the dose increases to 396 mg twice daily. Most patients remain on 237 mg twice daily long-term. The Endocrine Society's 2018 clinical practice guideline recommends initiating testosterone therapy in men with symptomatic hypogonadism who have consistently low serum testosterone levels measured on at least two morning samples 2.

Jatenzo Cash Price in Massachusetts in 2026

What Massachusetts Pharmacies Charge Without Insurance

The manufacturer list price for Jatenzo is approximately $900 per 30-day supply regardless of dose strength. Retail cash-pay prices across Massachusetts pharmacies in 2026 track closely to that list price, with only minor variation between chain and independent pharmacies. Goodrx coupons and pharmacy-specific discount programs occasionally shave $30, $80 off the cash price, but the savings are inconsistent and depend on which pharmacy honors the coupon on a given day.

For context, a 2023 analysis in JAMA Internal Medicine found the average net price for brand-name specialty drugs in the United States exceeded $130,000 per year for the highest-cost products, but mid-tier branded drugs like Jatenzo cluster between $8,000 and $12,000 annually before rebates 3.

Dose Strength Does Not Change the Price Meaningfully

All three Jatenzo capsule strengths (158 mg, 237 mg, and 396 mg) are priced similarly per fill, so titrating up to 396 mg twice daily does not produce a proportionally higher out-of-pocket cost at most pharmacies. Patients on the highest dose may receive a larger capsule count per prescription, but the monthly price remains in the same $900 range.

Where to Fill a Jatenzo Prescription in Massachusetts

CVS, Walgreens, Rite Aid, and independent compounding pharmacies licensed in Massachusetts all dispense Jatenzo. Mail-order pharmacy through a commercial plan's preferred network typically lowers the copay but does not reduce the cash price. Express Scripts, CVS Caremark, and OptumRx are the three largest pharmacy benefit managers operating in Massachusetts and each has negotiated a contracted rate with Tolmar, though the rebate savings rarely flow directly to the patient at the point of sale.

Massachusetts Medicaid (MassHealth) Coverage for Jatenzo

Coverage Status and Prior Authorization Criteria

MassHealth covers Jatenzo for adult male members diagnosed with hypogonadism, but the drug requires prior authorization (PA) under the MassHealth Preferred Drug List. The PA criteria align closely with the Endocrine Society guideline: confirmed diagnosis with at least two morning serum testosterone levels below 300 ng/dL, documented signs or symptoms of hypogonadism, and absence of contraindications such as prostate or breast cancer. MassHealth fee-for-service drug coverage details are published by the Executive Office of Health and Human Services 4.

How to Submit a PA for MassHealth

The prescribing clinician submits clinical documentation through the MassHealth PA portal or via fax to the contracted pharmacy benefit administrator. Required documents typically include laboratory reports showing low testosterone, the clinical note documenting hypogonadism symptoms, and attestation that the patient has a primary or secondary hypogonadism diagnosis per ICD-10 code E29.1 (primary testicular failure) or E23.0 (hypopituitarism). Approval decisions arrive within 72 hours for non-urgent requests. Appeals are available if the initial PA is denied.

MassHealth Managed Care Plans and Jatenzo

MassHealth members enrolled in a managed care organization (MCO) such as Tufts Health Together, Boston Children's ACO, or Fallon Health follow the MCO's own PA process rather than the fee-for-service pathway. Each MCO may use slightly different step-therapy requirements. Some MCOs require a trial of testosterone gel (e.g., AndroGel 1.62%) or intramuscular testosterone cypionate before approving Jatenzo. Documenting intolerance or contraindication to those alternatives can bypass the step-therapy requirement.

Commercial Insurance Coverage for Jatenzo in Massachusetts

Formulary Tier and Typical Copays

Most commercial insurance plans available through the Massachusetts Health Connector and employer-sponsored coverage in the state place Jatenzo on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays range from $60 to $150 per 30-day fill after deductible. Tier 4 copays range from $100 to $250 per fill, or 20 to 40% coinsurance on plans structured that way. High-deductible health plans (HDHPs) require the patient to satisfy a deductible (typically $1,500, $3,000 for individual coverage in 2026) before cost-sharing begins.

Step Therapy and Prior Authorization on Commercial Plans

Major commercial carriers in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim, Tufts Health Plan, and Aetna, require PA for Jatenzo. Step-therapy protocols vary. BCBS Massachusetts, for example, has historically required documented failure or intolerance of at least one generic testosterone formulation (injection or topical) before approving Jatenzo. An appeal supported by a detailed clinical letter from the prescribing physician has a reasonable chance of success when the patient has documented skin sensitivities to topical gels or needle phobia.

The FDA approved semaglutide for obesity in June 2021, and the parallel lesson from GLP-1 access battles is instructive: formulary denials fall most often when clinicians submit thorough clinical notes with objective laboratory data rather than brief cover letters 5.

Appealing a Denial in Massachusetts

Massachusetts law (M.G.L. Chapter 176O) requires insurers to provide a written denial with the clinical criteria used, an internal appeal process, and access to an independent external review through the Massachusetts Division of Insurance. Patients and prescribers can initiate an external review if the internal appeal fails. External reviewers overturn denials approximately 39 to 45% of the time for specialty drugs in states with strong independent review programs, according to a 2022 Health Affairs analysis 6.

The Tolmar Savings Card: How It Works for Massachusetts Patients

Eligibility and Savings Amount

Tolmar offers a commercial copay assistance card for Jatenzo that can reduce the out-of-pocket cost to $0 per month for eligible patients. The program applies to commercially insured patients only. Patients with any government-funded coverage, including MassHealth, Medicare Part D, or Tricare, are not eligible for the manufacturer savings card because of federal anti-kickback statutes. The savings card covers up to a program-specified dollar maximum per calendar year; Tolmar's program documents list an annual cap that has historically ranged from $2,400 to $3,600, which covers most or all of the patient cost-share for Tier 3 plans.

How to Enroll

Enrollment is available at Tolmar's patient support website (jatenzo.com). The prescribing clinician or patient completes a short online form, receives a card number or electronic voucher, and presents it at the pharmacy alongside the prescription. Most major chain pharmacies in Massachusetts accept the card. The savings card resets at the start of each calendar year, and patients must re-enroll or verify eligibility annually.

Income-Based Assistance

For patients who are uninsured or whose annual household income falls below 400% of the federal poverty level (approximately $60,240 for a single person in 2026), Tolmar's patient assistance program may provide Jatenzo at no cost. Applications require proof of income and insurance status. Processing typically takes two to four weeks. The NeedyMeds database also lists third-party foundations that cover testosterone therapy costs for men with hypogonadism 7.

Compounded Oral Testosterone Undecanoate in Massachusetts: Legality and Cost

503A Pharmacy Compounding Is Legal in Massachusetts

Compounded oral testosterone undecanoate prepared by a Massachusetts-licensed 503A pharmacy is legal under both federal and state law, provided the pharmacy dispenses the compound pursuant to a valid patient-specific prescription from a licensed prescriber. The FDA regulates compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Section 503A pharmacies may compound drugs on an individual prescription basis, even when an FDA-approved equivalent (Jatenzo) exists, as long as the compound is not on the FDA's Demonstrably Difficult to Compound list and the prescriber documents a clinical rationale 8.

Massachusetts Board of Registration in Pharmacy enforces additional state-level standards for compounding sterility and labeling. Pharmacies must hold an active compounding designation and pass periodic state inspections.

Cost of Compounded Oral Testosterone Undecanoate

Compounded oral testosterone undecanoate typically costs $0 to $150 per month at Massachusetts 503A pharmacies, depending on the dose and the specific pharmacy's pricing structure. Some telehealth platforms that operate in Massachusetts include the compounded medication in a bundled monthly subscription fee, effectively bringing the drug cost to $0 for the patient. This represents a potential savings of $750, $900 per month compared to the Jatenzo list price.

The trade-off is that compounded formulations are not FDA-approved for efficacy or manufacturing consistency. The pharmacokinetic data generated in the Swerdloff et al. PLUS trial specifically applied to the branded Jatenzo formulation 1. Compounded testosterone undecanoate capsules may have different bioavailability depending on the excipients and encapsulation method used by the compounding pharmacy.

Monitoring Is the Same Regardless of Formulation

Whether a patient uses Jatenzo or compounded oral testosterone undecanoate, the monitoring protocol is identical. Serum testosterone should be drawn 6 hours after the morning dose (to capture the pharmacokinetic peak-to-trough midpoint) at 28 days and then at 3-month intervals until stable. Hematocrit, PSA, and blood pressure monitoring follow Endocrine Society guideline intervals 2. The FDA prescribing label for Jatenzo includes a boxed warning for blood pressure increases; mean systolic blood pressure rose by 3.5 mmHg in the PLUS trial 9.

Telehealth Prescribing of Jatenzo in Massachusetts

Current Legal Status

Massachusetts permits telehealth prescribing of controlled substances, including Schedule III testosterone, subject to DEA and state licensing requirements. The DEA's COVID-19 telemedicine flexibilities that allowed prescribing without an in-person visit were extended through 2025, and proposed permanent rules published in the Federal Register would allow registered DEA practitioners to prescribe Schedule III, V substances via audio-video telemedicine after a single qualifying visit 10.

Massachusetts state law additionally requires that a valid prescriber-patient relationship exist, which most telehealth platforms satisfy through an initial video consultation, review of lab results, and documented clinical assessment.

What a Massachusetts Telehealth TRT Visit Includes

A standard telehealth testosterone evaluation in Massachusetts includes an intake questionnaire covering symptoms (using a validated tool such as the Androgen Deficiency in Aging Males questionnaire), a laboratory requisition for serum total testosterone (morning draw), LH, FSH, complete blood count, comprehensive metabolic panel, and PSA in men over 40. The physician reviews results and schedules a follow-up video visit to discuss diagnosis and treatment options. If Jatenzo is appropriate, the prescription is sent electronically to the patient's preferred Massachusetts pharmacy.

Telehealth vs. In-Person Cost Comparison

Telehealth initial consultations for testosterone therapy in Massachusetts range from $75 to $199 depending on the platform. In-person endocrinology visits may carry a specialist copay of $50, $150 under commercial insurance, plus the cost of laboratory work. Lab costs vary; a basic testosterone panel at Quest Diagnostics in Massachusetts runs approximately $30, $80 cash-pay. Direct-to-consumer lab services such as LabCorp and Walk-In Lab allow patients to order their own panels, potentially lowering total out-of-pocket cost before the clinical visit.

Side-by-Side Cost Comparison: Jatenzo vs. Alternatives in Massachusetts 2026

The table below summarizes realistic monthly costs across the most common testosterone replacement options available to Massachusetts residents in 2026.

| Option | Monthly Drug Cost (Cash) | Insurance Coverage | Notes | |---|---|---|---| | Jatenzo 237 mg twice daily (brand) | ~$900 | Yes, with PA | Savings card reduces to $0 for eligible commercial patients | | Compounded oral TU (503A pharmacy) | $0, $150 | Rarely covered | Legal in MA; bioavailability may vary | | Testosterone cypionate injection (generic) | $30, $60 | Yes, widely covered | Requires IM injection every 7 to 14 days | | Testosterone gel 1.62% (AndroGel generic) | $40, $90 | Yes, widely covered | Skin transfer risk; daily application | | Testosterone pellets (subcutaneous implant) | $300, $700/insertion, every 3 to 6 months | Variable coverage | Procedure required; not reversible short-term |

For men who prioritize oral administration and qualify for the Tolmar savings card, Jatenzo may cost the same or less per month than generic injectables after commercial cost-sharing. For uninsured patients or MassHealth members who do not qualify for the savings card, compounded oral testosterone undecanoate from a licensed 503A pharmacy is the lowest-cost oral option.

A 2021 analysis in Annals of Internal Medicine evaluated cost-effectiveness of testosterone therapy modalities and found that generic injectable testosterone cypionate remained the most cost-effective option across payer types, with branded oral formulations cost-effective only when accounting for adherence advantages and avoidance of injection-related adverse events 11.

Clinical Efficacy Data Supporting Jatenzo

The PLUS Trial: Key Outcomes

The key trial supporting Jatenzo's approval enrolled 166 adult men with hypogonadism across multiple U.S. Centers. After dose titration, 87% of participants achieved a mean serum testosterone concentration within the normal range (300 to 1,050 ng/dL) at steady state. Mean total testosterone at steady state was 489 ng/dL. Secondary endpoints showed statistically significant improvements in sexual function scores and lean body mass compared to baseline 1.

Cardiovascular Considerations

The FDA label for Jatenzo includes a boxed warning noting that the drug can cause increases in blood pressure that may raise the risk of major adverse cardiovascular events. In the PLUS trial, mean systolic blood pressure increased by 3.5 mmHg from baseline. Prescribers must confirm adequate blood pressure control before initiating therapy and monitor blood pressure regularly thereafter. The American Heart Association notes that hypertension affects approximately 47% of U.S. Adults and that any drug-induced blood pressure elevation warrants careful risk-benefit discussion 12.

Testosterone and Bone Density

A secondary benefit of testosterone replacement in hypogonadal men is improvement in bone mineral density. A 2020 systematic review and meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,574 pooled subjects) found testosterone therapy improved lumbar spine BMD by a mean of 0.04 g/cm2 (P<0.001) compared to placebo over 12 to 36 months 13.

Practical Steps for Massachusetts Patients in 2026

Step 1: Confirm the Diagnosis

Get a morning serum total testosterone level on two separate days. The Endocrine Society defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL, measured by an accurate assay 2. Free testosterone by equilibrium dialysis is useful when sex hormone-binding globulin is likely elevated or suppressed (obesity, liver disease, thyroid disorders).

Step 2: Contact Your Insurer Before Filling

Call the member services number on your insurance card and ask whether Jatenzo (NDC prefix: 70370) requires PA and what the formulary tier is. Ask specifically whether step therapy applies and what alternatives must be tried first. Get the PA fax number for your prescriber.

Step 3: Enroll in the Tolmar Savings Card Early

If you have commercial insurance, visit jatenzo.com and enroll before your first fill. The card number must be presented at the pharmacy at the time of dispensing; most pharmacies cannot retroactively apply the savings card to a previously paid claim.

Step 4: Explore Compounding If the PA Is Denied

If MassHealth or a commercial insurer denies the PA and the appeal fails, a licensed Massachusetts 503A compounding pharmacy can prepare oral testosterone undecanoate on a patient-specific prescription. Ask your telehealth or in-person prescriber for a prescription specifying the dose and formulation. Confirm the pharmacy holds a valid Massachusetts Board of Registration in Pharmacy compounding designation 14.

Step 5: Monitor Consistently

Serum testosterone drawn 6 hours post-morning dose at 28 days, then at 3 and 6 months, and every 6 to 12 months once stable. Hematocrit at 3 months and every 6 to 12 months thereafter. PSA annually in men over 40. Blood pressure at every clinical contact. A hematocrit above 54% requires dose reduction or temporary discontinuation per the prescribing label 15.